Core Viewpoint - The board of directors of Health元药业集团 has convened to approve several key reports and proposals during its twelfth meeting of the ninth session, emphasizing the company's commitment to transparency and governance [1][2][3]. Group 1: Meeting Details - The meeting was held on August 22, 2025, in Shenzhen, with all nine directors present, along with members of the supervisory board and senior management [1]. - The meeting was chaired by Chairman Zhu Baoguo and conducted via a combination of in-person and video conferencing [1]. Group 2: Resolutions Passed - The board approved the 2025 semi-annual report and its summary, which will be published on August 23, 2025, across various platforms [1]. - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025, with unanimous support [2]. - A mid-year evaluation report on the "Quality Improvement and Efficiency Enhancement Action Plan" was also approved, reflecting the company's ongoing strategic initiatives [2]. - The board passed a resolution to amend certain provisions of the company's sustainable development system, which has been reviewed by the sustainability committee [3]. - Additionally, the board approved amendments to the anti-corruption and anti-commercial bribery policy, also reviewed by the sustainability committee [3].

Group 1 - The Supervisory Board of the company reviewed the 2025 semi-annual report and its summary, concluding that the preparation and review procedures comply with relevant laws, regulations, and internal management systems [2] - The content and format of the semi-annual report and its summary meet the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange, accurately reflecting the company's operational management and financial status for the first half of 2025 [2] - The Supervisory Board confirmed that the personnel involved in the preparation and review of the semi-annual report did not violate confidentiality regulations [2] Group 2 - The Supervisory Board conducted a special report review on the management and actual use of raised funds for the first half of 2025, finding that the management and use of raised funds comply with regulatory requirements and the company's fundraising management system [2] - The use of raised funds was deemed legal and compliant, with no violations of laws or regulations that could harm shareholder interests identified [2]

《公司章程》和公司内部管理制度的各项规定，半年报及其摘要的内 容和格式符合中国证监会及上海证券交易所的各项规定，所包含的信息能够从各方 面真实地反映公司 2025 年半年度的经营管理及财务状况，参与半年报编制和审议的 人员无违反保密规定的行为。 证券代码：600380 证券简称： 健康元 公告编号：临 2025-059 健康元药业集团股份有限公司 九届监事会九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）九届监事会九次会议于 2025 年 8 月 12 日（星期二）以电子邮件并电话确认的方式发出会议通知并于 2025 年 8 月 22 日（星期五）公司九届董事会十二次会议结束后在健康元药业集团大厦 2 号会 议室以现场加视频会议形式召开。本次会议由监事会召集人余孝云召集并主持，应 参加监事三人，实际参加监事三人，会议的召开符合《公司法》及《公司章程》的 规定。本次会议以记名投票方式审议并通过以下议案： 一、审议并通过《对 <健康元药业集团股份有限公司 ensp=" ...

健康元药业集团 反腐败反商业贿赂制度 健康元药业集团股份有限公司 反腐败反商业贿赂制度 （经公司 2025 年 8 月 22 日召开的九届董事会十二次会议修订） 第一章 总则 第一条 为预防生产经营管理中的腐败，切实做好反商业贿赂、反腐败工作， 加强集团内控，强化制度监督与反腐，加强对重点、关键岗位的人员监督，确保 反腐败反商业贿赂长期有效，防止各种违法乱纪等不正当行为的发生，特制定本 制度。 第二条 本制度适用于集团总部及下属所有全资企业、控股企业和分公司（以 下统称：集团）。 第三条 集团一切生产经营管理活动或对外联活动，均应严格遵守本制度。 本条例中的活动包括但不限于与政府部门的接触、与客户代表洽谈订单、原材料 的采购、工程施工、产品销售、设备采购和维护等经济活动。 第四条 所有与集团有业务往来的客户、供应商、服务商、承包商均在本制 度管辖范围。 第二章 职责 第五条 集团风险管理部为集团反腐败反商业贿赂的监督管理部门。 第六条 监督管理部门的主要职责： （一）遵照国家有关政策、法律、法规及集团规章制度，开展集团反腐败、 反商业贿赂工作； （二）加强重要岗位、重要环节工作人员廉洁从业的管理和监督，在源头 ...

Core Viewpoint - The company has implemented the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance operational quality and maintain shareholder interests amidst a challenging economic environment and evolving pharmaceutical industry dynamics [1][2]. Group 1: Business Performance - The company reported a revenue of 7.898 billion yuan, a year-on-year decrease of 4.08%, while the net profit attributable to shareholders increased by 1.10% to 785 million yuan, and the net profit after deducting non-recurring gains and losses rose by 1.04% to 770 million yuan [2]. - The cash flow from operating activities reached 1.926 billion yuan, indicating strong operational resilience [2]. Group 2: Business Segments - In the chemical preparations segment, sales in the respiratory field declined due to ongoing procurement policies and intensified market competition, but the company responded by increasing market efforts for existing products, achieving a 112% year-on-year sales growth for a specific product [3]. - The health products segment performed well, growing by 35% year-on-year, supported by effective marketing strategies [3]. - The raw materials segment maintained stable operations, focusing on strategic customer collaborations and optimizing supply chain management to enhance market share [3]. Group 3: Innovation and R&D - The company has significantly increased its investment in innovative drug development, with over twenty first-class innovative drugs in the pipeline, more than ten of which have entered Phase II clinical trials [4][5]. - Recent advancements include a flu treatment capsule entering the production application stage and a pediatric flu treatment receiving IND approval, indicating progress in addressing diverse patient needs [4]. - The company aims to focus on unmet clinical needs in key therapeutic areas such as respiratory diseases, pain management, and autoimmune disorders, enhancing its competitive edge through differentiated product pipelines [5]. Group 4: AI Integration - The company has fully integrated artificial intelligence (AI) into its pharmaceutical innovation processes, enhancing drug development, production quality control, and marketing strategies [6]. - AI technologies are utilized for disease target identification, drug discovery, and clinical research, optimizing drug development pathways and improving efficiency [6]. Group 5: Corporate Governance - The company emphasizes strong corporate governance, adhering to relevant laws and regulations, and continuously improving its governance structure and internal controls [7]. - The company has held multiple shareholder meetings and board meetings to ensure accountability and transparency in decision-making processes [7]. Group 6: Investor Relations - The company prioritizes investor relations, implementing effective communication mechanisms to safeguard the rights of all shareholders, particularly minority investors [8][9]. - Recent initiatives include online interactive meetings and enhanced communication channels to address investor concerns and promote engagement [9]. Group 7: Shareholder Returns - The company has actively engaged in share buybacks and cash dividends, distributing 2.00 yuan per share to shareholders in 2024, with total cash dividends exceeding 1.6 billion yuan since 2020 [10]. - The company has conducted five share repurchase programs since 2020, investing nearly 2.7 billion yuan, demonstrating commitment to enhancing shareholder value [10]. Group 8: ESG Commitment - The company is dedicated to sustainable development, integrating ESG principles into its overall strategy and achieving recognition for its performance in environmental, social, and governance aspects [11][12]. - The company has set long-term carbon emission goals and actively participates in community health initiatives, reflecting its commitment to social responsibility [12]. Group 9: Management Accountability - The company has established incentive mechanisms for management to align interests with shareholders, including performance assessments tied to operational results [13]. - Continuous training and participation in regulatory meetings enhance the management's understanding of compliance and governance, supporting long-term stability [13]. Group 10: Ongoing Evaluation - The company will continue to assess the execution of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on core business and risk management to protect investor interests [14].

健康元药业集团 关于召开 2025 年半年度业绩说明会的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-063 健康元药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2025 年 9 月 19 日（星期五）15:00-17:00 ●会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频与网络文字互动 ●投资者可于 2025 年 9 月 12 日（星期五）至 9 月 18 日（星期四）16:00 前登录上证路演 中心网站首页点击"提问预征集"栏目或通过邮箱 joincare@joincare.com 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 健康元药业集团股份有限公司（以下简称：本公司）已于 2025 年 8 月 23 日披露 2025 年 半年度报告，为便于广大投资者更全面深入了解公司 2025 年半 ...

健康元药业集团 可持续发展管理制度 健康元药业集团股份有限公司 可持续发展管理制度 （经公司 2025 年 8 月 22 日召开的九届董事会十二次会议修订） 第一章 总则 第一条 健康元药业集团股份有限公司（以下简称：公司）为了贯彻和落实 科学发展观，构建和谐社会，推进公司可持续发展，根据《公司法》、 《证券法》、 《上海证券交易所股票上市规则》等法律、法规、规章和规范性文件的规定，结 合公司的实际情况，制定本制度。 第二条 本制度所称的公司可持续发展包括公司在践行环境保护、履行对利 益相关方责任、及完善公司治理等。 第三条 公司在追求经济效益及保护股东权益的同时，应充分维护债权人利 益，关注环境保护、社区利益、员工及客户权益，并积极促进产业链共同发展， 推动社会可持续发展。 第四条 公司在经营活动中，应遵循自愿、公平、等价有偿、诚实信用的原 则，遵守社会公德、商业道德，接受政府和社会公众的监督。不得通过贿赂、走 私等非法活动谋取不正当利益，不得侵犯他人的商标、专利和著作权等知识产权， 不得从事不正当竞争行为。 第五条 公司应按照本制度要求，定期评估公司可持续发展的履行情况，自 愿披露公司可持续发展报告。 第 ...

分组1 - Longi Green Energy reported a revenue of 32.81 billion yuan in the first half of 2025, a decrease of 14.83% year-on-year, with a net loss of 2.57 billion yuan, an improvement of 2.66 billion yuan compared to the previous year [1][2] - The company increased its silicon wafer shipments to 52.08 GW, with external sales of 24.72 GW, and battery module shipments of 41.85 GW, but faced losses due to market prices falling below cost levels [1][2] 分组2 - Vanke A reported a revenue of 105.32 billion yuan in the first half of 2025, a decrease of 26.23% year-on-year, with a net loss of 11.95 billion yuan, a decrease of 21.25% compared to the previous year [3][5] - The company completed the delivery of over 45,000 housing units and achieved a sales amount of 69.11 billion yuan, with a collection rate exceeding 100% [5][6] 分组3 - Tonghuashun achieved a revenue of 1.78 billion yuan in the first half of 2025, an increase of 28.07% year-on-year, with a net profit of 502 million yuan, up 38.29% [7][8] - The increase in revenue was attributed to a rise in user activity on its platform and increased demand for financial information services [7][8] 分组4 - Changan Automobile reported a revenue of 72.69 billion yuan in the first half of 2025, a decrease of 5.25% year-on-year, with a net profit of 2.29 billion yuan, down 19.09% [9][10] - The company achieved a sales volume of 1.355 million vehicles, a year-on-year increase of 1.6%, with new energy vehicle sales reaching 452,000 units, up 49.1% [9][10][11] 分组5 - Ping An Bank reported a revenue of 69.39 billion yuan in the first half of 2025, a decrease of 10.0% year-on-year, with a net profit of 24.87 billion yuan, down 3.9% [12][14] - The bank's net interest margin was 1.80%, a decrease of 16 basis points compared to the previous year [12][14] 分组6 - Longi Green Energy's net loss expanded to 4.955 billion yuan in the first half of 2025, with revenue of 40.51 billion yuan, a decrease of 7.51% year-on-year [26][28] - The company cited ongoing supply-demand imbalances in the industry as a significant challenge [26][28] 分组7 - China CNR reported a revenue of 119.76 billion yuan in the first half of 2025, an increase of 32.99% year-on-year, with a net profit of 7.25 billion yuan, up 72.48% [23][24][25] - The revenue increase was primarily driven by growth in railway equipment and new industry income [23][24] 分组8 - Jiangsu Bank reported a revenue of 448.64 billion yuan in the first half of 2025, an increase of 7.78% year-on-year, with a net profit of 202.38 billion yuan, up 8.05% [32][33] - The bank's total assets reached 4.79 trillion yuan, a growth of 21.16% compared to the previous year [32][33]

健康元药业集团 "提质增效重回报"行动方案评估报告 证券代码：600380 证券简称：健康元 公告编号：临 2025-062 健康元药业集团股份有限公司 关于"提质增效重回报"行动方案的半年度评估报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为践行"以投资者为本"的上市公司发展理念，维护公司全体股东利益，基 于对公司未来发展前景的信心、对公司价值的认可和切实履行社会责任，健康元 药业集团股份有限公司（以下简称：本公司）特制定"提质增效重回报"行动方 案 ， 具 体 内 容 详 见 公 司 2024 年 4 月 3 日 披 露 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《健康元药业集团股份有限公司 2024 年度"提质增效重回 报"行动方案》（以下简称：《行动方案》）。 为进一步落实有关工作安排，切实维护全体股东利益，公司对《行动方案》 在报告期内的执行情况进行全面评估并编制本评估报告，具体内容如下： 一、聚焦主业，提升经营质量 2025 年上半年，全球经济增长呈现放缓态势，地缘政治冲突与 ...

健康元药业集团 2025 年半年度募集资金存放与实际使用情况专项报告 证券代码：600380 证券简称：健康元 公告编号：临 2025-061 健康元药业集团股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 按照中国证监会《上市公司募集资金监管规则》、上海证券交易所颁布的《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》及相关格式指引等要求，现将 健康元药业集团股份有限公司（以下简称：本公司）截至 2025 年 6 月 30 日募集资金 存放与使用情况说明如下： 一、募集资金基本情况 （一）境内募集资金项目 1、2018 年配股实际募集资金金额和资金到账情况 经中国证券监督管理委员会（以下简称：中国证监会）核发的《关于核准健康元 药业集团股份有限公司配股的批复》（证监许可[2018]1284 号）批准，本公司 2018 年 向原股东配售 365,105,066 股新股。本次配股计划募集资金 200,000.00 万元，实际募集 资金总额为 171,5 ...